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Abstract
Background: Current day malaria cases and deaths are indicative of a lack of access to both methods of
prevention, diagnosis, and treatment; an important determinant of treatment efficacy is adherence. This study is a
follow up to the baseline study of adherence to artemether-lumefantrine (AL) carried out in Garissa District in 2010.
The study presented evaluates any changes in adherence levels which may have occurred in the area during this
period and after nearly three years of sustained use of ACT across the public health sector.
Methods: The study was carried out in Garissa County in the North Eastern Province of Kenya and included
patients fitting the suspected malaria case definition and having been prescribed AL, regardless of confirmatory
diagnosis. A questionnaire assessed the intake of AL via both self-reporting by the participant and observation of
blister packs by the interviewer. On separate occasions exit interviews with patients and observations of prescribers
were also carried out.
Results: Of the 218 participants enrolled, 195 were successfully followed up. 60% of participants were found to be
adherent to the three-day AL regimen, this is 4.7% lower than the proportion of participants adherent in 2010; the
result of a two-sided z-test was not significant (p = 0.23). The odds of the patient being adherent to AL increased
by 65% with each additional correct statement regarding how to take AL that a patient could recall (between zero
and four statements), this was the only variable significantly associated with patient adherence (p = 0.01).
Conclusion: Sustaining the ACT adherence rates at the 2010 levels, through 2.5 years of insecurity in the study area
is an achievement and suggests that if security can be improved barriers to improving health service quality and
patient adherence to AL would be removed. This study, by looking specifically at anti-malarial adherence over a
prolonged period and in a setting of severe conflict, provides a valuable and rare insight in to the challenges and
barriers to ACT adherence in such settings.
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Background
There were 198 million (range 124–283) cases of mal-
aria and 584,000 (range 367,000- 755,000) deaths from
malaria in 2013. These large figures are a considerable
decrease on the 2000 levels since when malaria cases
have dropped by 26% worldwide, and the number of
deaths due to malaria has fallen by 47% worldwide [1].
These reductions in morbidity and mortality are
testament to continuing efforts to improve access to
key malaria control interventions - LLINs, malaria
diagnostics and effective anti-malarials. The use of
anti-malarials has a long history, from the bark of Chinch-
ona trees containing quinine isolated in 1820, to the devel-
opment of chloroquine and then chloroquine-resistant
Plasmodium falciparum [2]. It was as part of the search for
new and safer anti-malarials that artemisinin-based drugs
emerged from China, becoming widely available outside of
China for the first time in the 1990s. With the hope of pre-
serving the efficacy of this anti-malarial it is recommended
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only in combined use with other anti-malarial, as artemisi-
nin combination therapy (ACT) [3]. Between 2003 and
2010 all malaria endemic countries in Africa switched to
using ACT as a first-line treatment for uncomplicated
malaria.
ACT has a more complicated dosing regimen than
monotherapies, in the case of artemether-lumefantrine
(AL) this ranges from one to four tablets (determined by a
patient’s weight) taken twice a day for three day. The effi-
cacy of ACT is very high, however, this is assuming a pa-
tient is adherent to the complete course of treatment [4-7].
The definition of full adherence differs between studies, in
this study self-reporting to have correctly taken the en-
tire course of treatment was the definition used. Regardless
of how defined, adherence is determined and affected by
numerous and intertwining factors including age of the
caretaker and patient, education level of the caretaker and
patient, perceptions of the disease, acceptance and know-
ledge of the treatment, cost of treatment, complexity of the
treatment schedule, quality of prescription, and the patient’s
clinical improvement, with these factors being associated
with either an increased or decreased likelihood of being
adherent [8-10]. The consequences of poor patient adher-
ence are serious; cure rates for patients are likely to be
lower, and repeat exposure to sub-lethal drug dosages risks
the development of parasite resistance to the active agents
in the drug formulations [11,12].
In Kenya, P. falciparum accounts for almost 100% of mal-
aria infections [1]; the main vectors are Anopheles gambiae,
Anopheles arabiensis, and Anopheles funestus [13]. Extrapo-
lating on the 2012 Kenyan population estimate of 43.18
million with the yearly growth rate of 2.7% [14], the esti-
mated population in 2014 is 45.54 million. 76% of the
population live in areas of malaria transmission (36% in
areas of high transmission, 40% in areas of low transmis-
sion) [15]. In 2013 there were 2, 335, 286 confirmed cases
of malaria in Kenya [1]. ACT in the form of AL is the first-
line treatment for uncomplicated malaria in Kenya. AL was
rolled out in 2006 after the very sudden decline in efficacy
of sulphadoxine-pyrimethamine (SP) [16].
The baseline study carried out by The MENTOR Initia-
tive in 2010 in Garissa County, North Eastern Province,
Kenya, found that of a sample of 272 patients, 176 (64.7%)
were “probably adherent”, defined as patients claiming to
have completed all doses whether or not they were able
to show the empty blister packet. The strongest predictor
of adherence was found to be patient knowledge of the
ACT regimen, if a patient was able to cite at least one cor-
rect instruction as to how to take AL they had 1.76 (95%
CI: 1.32, 2.35, p < 0.0001), the odds of being fully adherent
compared to a respondent that could not cite any instruc-
tions [17]. This study noted the importance of patient
awareness of the AL dosing regimen and focusing on health
worker training and prescribing practises.
Since the baseline study in 2010 The MENTOR Initiative
has supported the Ministry of Health (MoH) to reinforce
malaria case management in Garissa, through the introduc-
tion of rapid diagnostic testing (RDT) for patients with sus-
pected malaria, prior to treatment. Health workers received
regular technical coaching to encourage them to explain
the AL treatment regime to patients and there was a com-
prehensive package of malaria prevention activities. In
addition, and in line with the 2011 study recommendations
[17], Information, Education, and Communication (IEC)
and Behaviour Change Communication (BCC) campaigns
have been run in the study area. Materials such as radio
spots, posters, drama campaigns, and billboards and mural
paintings have been used to strengthen community aware-
ness on malaria prevention and treatment, including the
importance of adherence to the full course of ACT.
The purpose of this study is to measure current day
patient adherence to the three day AL treatment regi-
men, and determine any changes in adherence since the
2010 study. Whilst the 2010 study was conducted in the
areas of Bunyala, in Western Kenya, and Garissa, this
2013 study included only the area of Garissa; for this
reason all comparative analysis between the two studies
shall only take in to account the 2010 data collected in
Garissa.
Methods
Study area
Garissa County is located in what was formerly the
North Eastern Province of Kenya and covers an area of
44,175 square kilometres (km2). It borders Wajir County
to the North, Tana River County to the West, Lamu
County to the South, and Isiolo to the North West and
shares an international boundary with Somalia to the
East (Figure 1). The population is 95% ethnic Somali
and according to the last national census in 2009 was
623,060 [18]; expected to have grown to 715, 312 in
2014 based on the UNICEF prediction of a 2.8% annual
growth rate [19].
Garissa County comprises six districts namely Garissa,
Balambala, Lagdera, Ijara, Dadaab, and Fafi. There are 62
public and private health facilities in Garissa County, in-
cluding those serving Dadaab Refugee Camp. The climate
is semi-arid with a range in temperature from 21°C to 39°C
in 2012 [20] and an annual average bimodal rainfall (rainy
seasons from March – May and September – October) of
250 – 300 mm. Data collection started in June 2013 and
continued through to the end of October 2013, overlapping
with the long and often heavy rainfall from September
onwards.
Malaria transmission in Garissa is strongly seasonal;
low during most of the year but epidemic prone during
the rainy season [21]. In 2013, there were 4,519 clinical
cases of malaria and 1,321 confirmed cases of malaria in
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Garissa, this is a 92% reduction in both clinical and diag-
nosed malaria cases in the area since 2010 (unpublished
Kenyan Ministry of Health data). The primary vectors in
the region are mainly exophagic and exophilic, such as
An. coustani and An. arabiensis [22-24]. Both P. falcip-
arum and P. vivax are present with P. falciparum ac-
counting for the vast majority of cases [1,25].
Historically, due to poor understanding that not all fe-
vers are malaria and that malaria is seasonal, and a
general lack of confidence in health systems (especially
among the ethnic Somali communities), malaria has
been greatly over-diagnosed in this area. Diagnostic tools
have either been unavailable, misused, negative results
not believed, or diagnosis has been based on clinical
symptoms alone [26].
Study population
All study participants were patients whose symptoms fit-
ted the definition of a suspected malaria case: fever (axil-
lary temperature ≥37.5°C) or history of fever in the last
Figure 1 Map of Garissa County, Kenya.
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48 hours with other obvious causes of fever excluded
(typhoid, yellow fever, dengue fever, diphtheria, Rift Val-
ley fever, among others [27,28]), patients considered for
a malaria diagnostic test, weight ≥5 kg, age >5 months,
and with no signs of complicated malaria or other severe
disease. Those who fitted this definition and were
treated with AL were included as a study subject regard-
less of whether or not the diagnosis was confirmed. Pa-
tients were excluded from the study if they had suffered
from a separate episode of malaria in the previous two
weeks, or if they or a household member had previously
participated in the study, this ensured that no family was
interviewed twice.
Study procedure
Six health facilities in Garissa were involved in the study,
three of which had participated in 2010. Health workers
at the health facilities informed their patients to keep
the empty AL blister packs after treatment had been
completed. Patients were not told why they were being
asked to keep the blister packs in order to maintain the
validity of the results. At the end of each day, the regis-
ters of the health facilities were consulted to identify pa-
tients who met inclusion criteria, these patients or their
caretakers were visited at home by the study team and
community health workers on the fourth day after re-
ceiving treatment.
At the beginning of the household visit, written con-
sent was requested from each adult patient, and the par-
ent or guardian of every child patient included in the
study. The patient’s axillary temperature was taken. A
structured questionnaire – available in English and
translated into Somali and field-tested – was given to
the participants. The questionnaire assessed the intake
of AL via both self-reporting by the participant and ob-
servation of blister packs by the interviewer. Socio-
demographic information on the patient was collected
and the patient or caretaker’s language, age and educa-
tion level, the number of people who spent the previous
night at the house, and the number of children cared for
were all recorded.
The questionnaire was concluded by counting any
remaining tablets. In cases where tablets remained, pa-
tients/caretakers were asked to specify why not all tab-
lets were taken by the patient/ given to the child.
Questions were asked in such a way that honest answers
were encouraged, without placing blame on inter-
viewees. The team of interviewers were supervised by
MENTOR Initiative clinical staff.
Patients were categorized as definitely non-adherent;
probably non-adherent; and probably adherent based on
the following classifications. Those who presented blister
packs with AL doses still remaining were definitely non-
adherent; patients or caregivers who claimed doses not
completed but who did not show a blister pack were
classified as probably non-adherent; those who claimed
to have completed all doses and could show an empty
blister pack were classified as probably adherent as were
patients who could not show an empty blister pack but
claimed to have taken all of the tablets. Non-adherent
patients were advised to return to the health clinic for a
new assessment to avoid negative consequences from an
incomplete course of treatment.
In order to identify possible factors influencing adher-
ence, two additional investigations were carried out. The
week after the completion of collection of adherence
data, patients or their caretakers were systematically
interviewed after leaving the pharmacy (out of sight of
the pharmacy in order to reduce bias) to assess how well
they had understood the AL prescription. A short ques-
tionnaire, asking for a spontaneous account of how the
treatment was to be taken/ given to the child, was car-
ried out followed by systematic questioning for each
treatment dose.
On separate occasions the pharmacists or other per-
sons dispensing medication in each health facility were
systematically observed while explaining the AL pre-
scription to patients or caretakers. A check-list was used
to verify what information was given: e.g. timing of drug
intake, importance of completing the treatment. The ob-
servers stood next to the patient during the explanation
so the pharmacist/person dispensing the medication
knew a study was being conducted, but he/she was
blinded as to the purpose of the observation.
Analysis
Open-ended questions were reviewed and grouped into
thematic categories that were coded for data entry. Re-
sults were double entered into Epi Info 3.5.1 (CDC,
WHO) and all data were analysed in STATA 13.0 (Stata
Corporation, College Station, Texas). Data were summa-
rized using proportions and means and medians, where
appropriate. Comparisons of proportions between cat-
egorical variables were made using two-tailed Z-tests.
Univariate and multivariate logistic regression was used
to test for significance between potential explanatory
variables and the dichotomous outcome variable of the
patient being adherent or not. Significance tests were de-
termined at the 10% level.
Ethical consideration
The study was not an intervention study and was not
designed to influence the diagnosis and treatment of the
participants. Permission to carry out the study was
gained from the University of Nairobi, The Ministry of
Health, Kenya, and Kenya National Hospital ethics re-
view committee.
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At the beginning of the visit written consent was re-
quested from every adult and parent or guardian of
every child considered for inclusion in the study.
Results
Description statistics
A total of 218 respondents were enrolled in the study.
They came from six health facilities from within Garissa
district (Garissa town, capital of Garissa County). Of
these enrolled participants 23 (10.5%) were either lost to
follow-up (n = 19) or didn’t respond to later questioning
(n = 4), bringing the total number of participants suc-
cessfully followed-up down to 195. The majority of par-
ticipants were male (81.0%) and over 15 years of age
(99.0%), half of participants owned their own businesses
(53.8%), when asked about education 32.3% reported
never having attended a school or college, just over half
of all households contained 0–5 people (55.4%) with the
remaining containing six or more people. Characteristics
of the study population are shown in Table 1.
Patient adherence
Of the 195 participants successfully followed up, 60.0%
were found to be probably adherent to the three day ACT
regimen. Of the 78 participants classified as non-adherent,
31 (39.7%) were definitely non-adherent and 47 (60.3%)
were probably non-adherent. This proportion of patients
found to be probably adherent in 2013 is 4.7% lower than
the proportion of participants probably adherent in 2010.
The result of a two-sided z-test between the proportion ad-
herent in 2010 and 2013 was not significant at the p ≤ 0.05
level (Table 2).
Other notable differences between the study popula-
tions include differences in the sex and age of partici-
pants. In the 2010 study population of Garissa the
proportion of female to male participants was greater
than it was in 2013; in 2010 there were 160 females
(55.8%) and 112 males (44.2%), in 2013 there were only
37 females (19.0%) and 158 males (81.0%). In 2013 the
proportion adherent differed slightly between male and
female, 59.5% probably adherent and 62.2% probably ad-
herent, respectively. The 2010 study population also
contained many more participants under the age of
15 years. In 2013 only two study participants (1%) were
children under 15 years of age compared to the 136 par-
ticipants (50%) in the 2010 study population in Garissa.
Of the 2013 study population the majority tested RDT
positive for malaria (80.5%) with 37 participants testing
negative (18.9%), one participant did not know their
RDT result (0.5%).
Univariate logistic regression compared 17 variables
thought to be potential predictors of patient adherence. Of
these 17 variables, 11 were not fitted in to a multivariate lo-
gistic regression model as their crude (bivariate) odds ratios
were not significant (p ≥ 0.10); one variable- whether or not
the patient had difficulty in understanding the prescription
instructions- was excluded as collinearity with adherence
was shown. The remaining five variables with p-values
≤0.10 were fitted in to the multivariate logistic regression
model (Table 3). The only variable significantly associated
with patient adherent to a course of AL treatment in the
multivariate model was the number of correct statements
regarding how to take AL that the patient could recall
(p = 0.01). The odds of the patient being adherent to AL in-
creased by 65% with each additional statement they could
recall (between zero and four statements).
Patient’s knowledge and perceptions
The follow up questionnaire/survey of patients four days
after their visit to the health facility and their being pre-
scribed ACT collected information on their knowledge
Table 1 Descriptive characteristics of the study
population
Variable N % (95% CI)
Patient sex
Male 158 81.0 (74.8, 86.0)
Female 37 19.0 (14.0, 25.2)
Patient age
≤15 years 2 1.0 (0.25, 4.1)
>15 years 193 99.0 (95.9, 99.7)
Patient education
Never attended 63 32.3 (26.1, 39.2)
Primary 55 28.2 (22.2, 35.0)
Secondary 48 24.6 (19.0, 31.2)
Post-secondary 25 12.8 (8.8, 18.3)
Not applicable 4 2.1 (0.8, 5.4)
Head of household’s job
Farming 1 0.5 (−0.4, 1.4)
Own Business 105 53.8 (47.2, 60.4)
Retired 1 0.5 (−0.4, 1.4)
In school 2 1.0 (−0.3, 2.3)
Other 50 25.6 (19.8, 31.4)
Unemployed 36 18.5 (13.4, 23.7)
Household size
0-5 people 108 55.4 (48.3, 62.3)
≥6 people 87 44.6 (37.7, 51.7)
Table 2 Comparative analysis of adherence in Garissa in
2010 and 2013
Year Total
participants
Probably
adherent
% probably adherent
(95% CI)
2010 272 176 64.7 (59.0 70.4) p = 0.23
2013 195 117 60.0 (52.9, 66.7)
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and perceptions regarding malaria and its treatment.
Table 4 shows that the majority (77.4%) of patients had
waited less than a day from when first experiencing
symptoms before visiting a health facility. Nearly all pa-
tients (93.3%) reported having seen AL before and more
than half had taken AL before (64.3%). Only a small pro-
portion of patients reported disliking AL (3.1%) while a
fifth (21.5%) reported side-effects to the treatment. Of
side effects reported, the most common was vomiting
(82.6%) followed by fever (10.9%). When asked about
prescription practices, 95.4% of patients could report at
least one correct statement while 53.9% could report at
least two or more statements; correct statements in-
cluded the timing of taking doses, taking doses with food
or milk, and returning to a health facility if condition de-
teriorated. Just over half of patients (56.7%) reported not
to have had malaria in the last month. Almost all pa-
tients (98.5%) reported having had an RDT test, of these
80.5% reported testing positive for malaria.
Observations and exit interview questionnaire
Data collected via both observations of prescriptions and
exit interviews (Table 5) showed taking doses in the
morning and evening for the two days after the first dose
is the message most frequently given to patients. Repeat-
ing doses in the case of the patient vomiting within
30 minutes of taking the original dose was the least fre-
quently stated message in both contexts.
Discussion
The ACT adherence study carried out in 2010 in Garissa
and Bunyala was the first of its kind in Kenya and was
important in informing the Ministry of Health nation-
ally, and regionally, on the success of the introduction of
ACT since 2006, and the factors associated with either
high or low levels of adherence [17]. The follow-up
study carried out in Garissa in 2013 and presented here
allows for comparisons of ACT adherence levels three
years on and after a period of consistent activity by the
Table 3 Bivariate (crude) and multivariate (adjusted) model of association between adherence and exposure variables
Variable Adherent
(%)
Non adherent
(%)
Crude odds ratio
(95% CI)
P-value Adjusted odds
ratio (95% CI)
P-value
Patient education 0.06 0.18
Never attended 29 (46.0) 34 (54.0) 1 1
Primary 40 (72.7) 15 (27.3) 3.13 (1.44, 6.77) 2.44 (1.05, 5.67)
Secondary 30 (62.5) 18 (37.5) 1.95 (0.91, 4.20) 2.06 (0.90, 4.72)
Post-secondary 16 (64.0) 9 (36.0) 2.08 (0.80, 5.42) 2.84 (0.96, 8.46)
Not applicable 2 (50.0) 2 (50.0) 1.17 (0.16, 8.85) 1.55 (0.10, 24.60)
Price paid for treatment 0.05 0.07
Nothing 98 (63.6) 56 (36.4) 1 1
10 Kenyan Shillings 1 (100) 0 - -
Other Amount 17 (46.0) 20 (54.1) 0.49 (0.24, 1.00) 0.46 (0.21, 1.02)
Don’t know 1 (33.3) 2 (66.7) - -
Who provided treatment 0.04 0.79
Clinic/HF pharmacist 104 (63.8) 59 (36.2) 1 1
Doctor/ clinical officer/ nurse 9 (36.0) 16 (64.0) 0.32 (0.13, 0.77) 0.65 (0.05, 8.47)
Private pharmacy 0 1 (100) - -
Community Health Worker 3 (60.0) 2 (40.0) 0.85 (0.14, 5.24) 0.44 (0.03, 6.15)
Don’t know 1 (100) 0 - -
Who explained how to take 0.01 0.62
Clinic/HF pharmacist 105 (63.3) 61 (36.8) 1 1
Doctor/ clinical officer/ nurse 7 (33.3) 14 (66.7) 0.29 (0.11, 0.76) 0.50 (0.03, 7.77)
Private pharmacy 0 1 (100) - -
Family member/friend 1 (100) 0 - -
Community Health Worker 1 (33.3) 2 (66.7) 0.29 (0.3, 3.27) -
Other 2 (100) 0 - -
Number of statements recalled by patient 0.002 0.01
Each additional correct statement recalled by patient (0–4) 117 (60.0) 78 (40.0) 1.78 (1.25, 2.54) 1.65 (1.10, 2.46)
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MoH aimed at consolidating and improving the quality
of malaria case management services across Garissa.
Similar studies in to the adherence of patients to different
treatment regimens for uncomplicated malaria show vary-
ing results. Using self-reporting, pill counts, and blood drug
levels to investigate the adherence of patients to a six dose
regimen of AL in Uganda found 90% of patients to be prob-
ably adherent [29]. In the Maheba refugee settlement of
Zambia, 39.4% of patients were classified as probably ad-
herent to a three-day course of the combination of
artesunate and SP, 21.2% were certainly non-adherent, and
39.4% were probably non-adherent [30].
The 4.7% decrease in proportion adherent in Garissa
from the 2010 level of 64.7% is not statistically significant
and so should be interpreted as no significant change in ad-
herence levels between the years, rather than a true de-
crease. This result is disappointing, however, the lack of
apparent improvement does not mean the data is of no
interest, nor does it reflect the improvements seen in the
uptake and usage of RDTs and ACT by health workers
across the region [26]. Possible explanations for an un-
changed level of adherence include limitations to the study
design and differences between the two study populations
in 2010 and 2013, contextual reasons outside the control of
the programme and/or flaws and/or oversights in the efforts
to achieve behaviour change during the intervention period.
Differences in the study populations between 2010 and
2013 in Garissa may have impacted the adherence levels
seen. The sample size of patients in 2013 (n = 195) was
much smaller than the sample size in the 2010 study
(n = 918) [17]. This drop in patient numbers is due in part
to the reduced sampling area in 2013, the exclusion of
Bunyala which was sampled in 2010, and also to the great
reduction in the number of clinical and confirmed malaria
cases over the three year period (both reduced by 92%).
Whilst this reduced sample size may have limited the power
of the study it is great testament to malaria control and pre-
vention work carried out in the area. There were also
changes in sex and age of study participants between 2010
and 2013. The proportion of male participants was far
greater in 2013 than in 2010 (81.0% compared to 41.2%, re-
spectively) and the proportion of study participants under
the age of 15 years was much smaller in 2013 compared to
2010 (1% compared to 50%, respectively). Although neither
sex nor patient age were shown to be statistically associated
with adherence, differences such as these in the study popu-
lations are potential limitations to comparative analysis be-
tween adherence levels in 2010 and 2013.
The methods used to measure adherence and the cat-
egorisation of patients as adherent or not differ between ad-
herence studies. The majority of methods can be
summarised with five overarching approaches; “Completed
treatment” identifying individuals who say they completed
treatment, “verified completed treatment” corroboration of
reported completed treatment with a pill count, “timely
completion” refers to patients reporting timely completion,
“verified timely completion” refers to those reporting timely
completion and with a pill count to confirm no tablet left.
The last method is “biological assay” which uses the detec-
tion of sufficient levels of the drug in biological samples to
confirm adherence [10]. The method used in this study-
verified completed treatment- does not attempt to deter-
mine whether or not the patient took the AL doses at the
correct timings, simply whether or not the complete course
Table 4 Patients malaria knowledge and perceptions
Variables N % (95% CI)
Days waited before visiting health facility
≤1 day 151 77.4 (71.0, 82.8)
>1 day 44 22.6 (17.2, 29.0)
Patient Seen AL before
Yes 182 93.3 (88.8, 96.1)
No 12 6.2 (3.5, 10.6)
Don’t Know 1 0.5 (0.1, 3.6)
Patient Taken AL before
Yes 63 64.3 (54.2, 73.3)
No 35 35.7 (26.7, 45.8)
Dislike AL
Yes 6 3.1 (1.4, 6.7)
No 189 96.9 (93.3, 98.6)
Side Effects
Yes 42 21.5 (16.3, 27.9)
No 153 78.5 (72.1, 83.7)
Fever 5 10.9 (1.9, 19.9)
Vomiting 38 82.6 (71.6, 93.6)
Headache 2 4.3 (−1.6, 10.6)
Weak & dizzy 1 2.1 (−2.0, 6.2)
Number of correct statements recalled
None 9 4.6 (2.4, 8.7)
At least one 186 95.4 (91.3, 97.6)
Last time patient had malaria
≤1 month ago 88 43.4 (36.6, 50.3)
>1 month ago 115 56.7 (49.7, 63.4)
Did patient receive RDT
Yes 192 98.5 (95.3, 99.5)
No 0 0
Don’t know 3 1.5 (0.5, 4.7)
RDT Result
Negative 37 18.9 (14.0, 25.2)
Positive 157 80.5 (74.3, 85.5)
Don’t know 1 0.5 (0.07, 3.6)
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of treatment was taken. Whilst this method is vulnerable to
misreporting by patients and skewing of results in ways that
biological assays are not, it has been used in similar adher-
ence studies to obtain realistic and valuable results
[17,31,32].
While policy is to give ACT for free at health facilities,
the study has shown that this is often not the case. 37
patients (19%) reported paying for their treatment; the
largest proportion of these paid 100 Kenyan Shillings
(KSH) (n = 22, 59.5%), equivalent to one United States
Dollar (USD), five people paid less, and nine paid more.
The highest price reported was 800 KSH. Of those re-
portedly paying for treatment, 83.8% (n = 31) received
treatment from a clinical pharmacist, 13.5% (n = 5) re-
ceived treatment from a doctor, or nurse, and 2.7% (n =
1) received treatment from a private pharmacy. The pro-
portion of Kenyans living below the international pov-
erty line of 1.25 USD per day (roughly 110 KSH) is
43.4% [33]. Having to pay even 30 KSH (the lowest price
reported), let alone 100 KSH or above, is a significant
proportion of this total daily allowance. While this evi-
dently hasn’t been a deterrent to seeking health care
among this study population - participants are patients
who have been prescribed AL and paid the costs asked
for – it is possible that care takers and patients that have
to pay for treatment may sub-divide treatments between
multiple family members, or save part of the treatment
for future malaria cases in the family [34,35]. It is feas-
ible that either patients do not trust the dosing advice
given by prescribers once they learn they have been mis-
informed about the price of ACT; or that they in fact
pay more attention to the advice of the prescriber purely
because they are paying for the treatment. Whilst it was
not shown in this study that the price of treatment was
associated with patient adherence, the issue of pricing is
one that should be addressed in order to ensure free
malaria diagnosis and treatment is available to all, from
prescribers trusted by the patient.
Interventions aiming to improve patient adherence to
a treatment regime have been numerous and varied.
From improving adherence to short-term treatments,
such as anti-malarials, to treatments for chronic condi-
tions, such as hypertension, various methods have been
investigated including changing dosing schedules (for
example, from two tablets a day to one), reminder pill
packaging, individual counselling, home visits by re-
search assistants, and reward schemes for high adher-
ence [36,37]. A study in Ghana found that increased
provision of information to clients by providers in pri-
mary health care facilities resulted in increased levels of
adherence; improvements were most marked in the
clinic that was found to be worst performing at the be-
ginning of the study [38]. A BCC intervention in Kenya,
which involved the training of drug vendors to treat
childhood fevers with chloroquine and provided age-
specific dosing charts saw adherence to the correct age-
specific dose increase from 4% to 75% and correct dur-
ation from 23% to 47% [39]. Studies and results of this
nature provide information on how to tailor IEC/BCC
campaigns towards specific communities and contexts.
In the study area of Garissa the ethnic Somali popula-
tion is a marginalized one anecdotally sceptical of out-
side interventions and IEC campaigns, making the
challenge of real behaviour change even greater. The
number of correct statements reported by the patient
was the most significant variable in predicting adherence
in this survey and the 2010 survey [17], this result em-
phasises the important of patient IEC campaigns and the
clear and correct relay of information from the pre-
scriber to the patient. Results from exit interviews and
prescription observations showing that the majority of
treatment regime messages are being given to more than
half of patients suggest that many patients have at least
some knowledge of how to correctly take AL treatment;
considered alongside the relatively low adherence rate of
60% this suggests that IEC campaigns must go along side
Table 5 Data collected via observation and exit interviews about the messages given to patients by prescribers
Data collected via observations of prescription
n = 90
Data collected via exit interviews
n = 89
Message given to patient N % (95% CI) N % (95% CI)
Take first dose straight away 68 75.6 (65.4, 83.5) 68 76.4 (66.3, 84.0)
Take second dose 8 hours after first 56 62.2 (51.6, 71.8) 31 34.8 (25.5, 45.5)
Take remaining doses in morning and evening for 2 days 70 77.8 (67.8, 85.3) 83 93.3 (85.6, 97.0)
All three above messages on timings 44 48.9 (38.6, 59.3) 31 34.8 (25.5, 45.5)
Take tablets for 3 days 63 70 (59.6, 78.7) - -
Take all the tablets 62 68.9 (58.4, 77.7) 79 88.8 (80.2, 93.9)
Take with food/milk 19 21.1 (13.8, 31.0) 17 19.1 (12.1, 28.8)
Repeat dose if vomit within 30 minutes 12 13.3 (7.6, 22.2) 9 10.1 (5.3, 18.5)
Return to health facility if deteriorate 17 18.9 (4.1, 12.0) 19 21.4 (13.9, 31.3)
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campaigns informing patients of the important and ben-
efits of being adherent and encouraging them to act on
the knowledge they have.
Local contextual factors are also likely to have had an
effect on adherence levels. Security in Garissa has histor-
ically been fragile. From 2010 onwards conflict inside
Somalia intensified resulting in significant influxes of
new refugees into the camps in Garissa Town. In Octo-
ber 2011, Kenya sent 10,000 troops into southern
Somalia, largely through Garissa, to attack and clear Al
Shabaab terrorist groups that controlled areas neigh-
bouring Garissa [40,41]. The Kenyan military presence
in South Central Somalia has been maintained since that
time as part of an international effort to bring peace to
the country. One side effect of the ongoing Kenyan mili-
tary operation into southern Somalia has been a dra-
matic escalation of Al Shabaab incursions into Garissa
County and attacks on the Kenyan public [42]. Whilst
Garissa Town has suffered only sporadic attacks and has
been the least affected area in the county, any increases
in instability are likely to have had indirect effects on
health services. The Somali population in the area, likely
to have made up the largest proportion of the study par-
ticipants, are anecdotally untrusting of outside interven-
tion, including the health care system. As results have
shown education levels in the area are very low and are
likely to greatly impact understanding and knowledge of
malaria which is shown to be a significant predictor of
adherence. The insecurity has also meant that staff turn-
over in health facilities has been very high and the facil-
ities typically do not attract the highest quality of staff,
again likely to comprise the clarity and quality of health
care given to patients, including AL treatment regime
information. In this particular setting, conflict is sus-
pected to have had an impact both on the ability of the
health care system and health care workers to sustain
the quality of services provided in times of peace.
Achieving patient behaviour change in settings such as
these when the priorities of communities are focused
largely on survival and coping mechanisms becomes an
even greater challenge.
Conclusion
This paper has laid out the findings of an ACT adher-
ence study in Garissa County, Kenya, nearly three years
after a base-line study and efforts to improve ACT pre-
scription practices and adherence. Results showed no
significant change in adherence levels over the period.
The ability of patients to recall prescription practise
statements was significantly associated with adherence, a
finding important in informing future interventions
aimed at improving adherence. Changes in the study
populations, successes and failures of prescribers to pro-
vide accurate and free health care, and the challenging
security context of the area are all possible explanations
for the lack of an increase in adherence levels. Given all
of these factors, sustaining the ACT adherence rates at
the 2010 levels, through three years of insecurity is an
achievement and suggests that if security can be im-
proved barriers to improving health service quality and
patient adherence to ACT could be removed.
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